2. NF-κB Metabolic Enzyme/Protease Immunology/Inflammation Apoptosis
  3. IKK Heme Oxygenase (HO) Keap1-Nrf2 Reactive Oxygen Species (ROS) Ferroptosis
  4. JHB-17

JHB-17 is an IKKβ inhibitor with blood-brain barrier permeability, with an IC50 of 1.1 μM and a KD of 1.293 μM. JHB-17 is a non-ATP competitive inhibitor targeting the allosteric site of IKKβ, and it inhibits the phosphorylation of IKKβ. JHB-17 promotes the nuclear translocation of Nrf2, upregulates the expression of HO-1, SLC7A11 and glutathione, and reduces ROS to exert antioxidant effects. JHB-17 reduces cerebral infarction volume and improves neurobehavioral function. JHB-17 can be used in the research of cerebral ischemia-reperfusion injury.

For research use only. We do not sell to patients.

JHB-17

JHB-17 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

JHB-17 Related Antibodies

Top Publications Citing Use of Products

View All IKK Isoform Specific Products:

View All Isoforms
IKK-α IKK-β IKK IKKε TBK1

View All Heme Oxygenase (HO) Isoform Specific Products:

View All Isoforms
HO-1 HO-2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

JHB-17 is an IKKβ inhibitor with blood-brain barrier permeability, with an IC50 of 1.1 μM and a KD of 1.293 μM. JHB-17 is a non-ATP competitive inhibitor targeting the allosteric site of IKKβ, and it inhibits the phosphorylation of IKKβ. JHB-17 promotes the nuclear translocation of Nrf2, upregulates the expression of HO-1, SLC7A11 and glutathione, and reduces ROS to exert antioxidant effects. JHB-17 reduces cerebral infarction volume and improves neurobehavioral function. JHB-17 can be used in the research of cerebral ischemia-reperfusion injury[1].

IC50 & Target[1]

IKKβ

1.1 μM (IC50)

IKK-β

1.293 μM (Kd)

HO-1

 

In Vitro

JHB-17 potently inhibits IKKβ kinase activity in a cell-free system with an IC50 of 1.1 μM, which is approximately 70 times more potent than EF24; it has a KD of 1.293 μM for binding to wild-type IKKβ, and its binding affinity to IKKβK428A and IKKβQ432A mutant proteins is reduced[1].
JHB-17 (0.625-5 μM; 1 h or 18 h) increases the survival rate of H2O2-damaged SH-SY5Y cells in a concentration-dependent manner[1].
JHB-17 (5 μM; 1 h or 18 h) significantly reduces lipid peroxidation levels (MDA levels) and ROS accumulation in SH-SY5Y cells damaged by H2O2 after 1 h or 18 h of pretreatment[1].
JHB-17 (5 μM; 6 h) promotes Nrf2 nuclear translocation[1].
JHB-17 (1.25-5 μM; 18 h) upregulates the expression of HO-1 protein in SH-SY5Y cells in a dose-dependent manner[1].
JHB-17 (5 μM; 18 h pretreatment, 6 h H2O2 exposure) inhibits H2O2-induced phosphorylation of IKKβ and upregulates the expression of HO-1 protein in SH-SY5Y cells after 18 h of pretreatment followed by 6 h of H2O2 exposure[1].
JHB-17 (5 μM; 18 h pretreatment, followed by 24 h H2O2 exposure) loses its cytoprotective effect against H2O2-induced damage in SH-SY5Y cells when IKKβ is overexpressed, which confirms that IKKβ is its key target[1].
JHB-17 acts in a dose-dependent manner, and this effect occurs after 18 h of pretreatment followed by 2 h of exposure to H2O2[1].
JHB-17 (1.25-5 μM; 18 h pretreatment, 24 h H2O2 exposure) upregulates the expression of SLC7A11, increases intracellular GSH levels and reduces lipid ROS, and inhibits H2O2-induced ferroptosis in SH-SY5Y cells in a dose-dependent manner[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

JHB-17 Related Antibodies

Cell Viability Assay[1]

Cell Line: SH-SY5Y human neuroblastoma cells (H2O2-induced oxidative damage model)
Concentration: 0.625, 1.25, 2.5, 5 μM
Incubation Time: 1 h or 18 h (pretreatment); 24 h (H2O2 exposure)
Result: Protected SH-SY5Y cells from H2O2-induced damage in a concentration-dependent manner for both 1 h and 18 h pretreatments, with significant protective activity observed at concentrations as low as 0.625 μM.

Immunofluorescence[1]

Cell Line: SH-SY5Y cells
Concentration: 5 μM
Incubation Time: 6 h
Result: Significantly enhanced Nrf2 fluorescence signal within the nuclei of SH-SY5Y cells, indicating increased Nrf2 nuclear translocation.

Western Blot Analysis[1]

Cell Line: SH-SY5Y cells
Concentration: 1.25, 2.5, 5 μM
Incubation Time: 18 h
Result: Dose-dependently increased HO-1 protein levels in SH-SY5Y cells after 18 h incubation.
At 5 μM, induced stronger HO-1 expression than JHA-7 and TBHQ.
Upregulated the expression of SLC7A11.

Western Blot Analysis[1]

Cell Line: SH-SY5Y cells (H2O2-induced oxidative damage model)
Concentration: 5 μM
Incubation Time: 18 h (pretreatment); 6 h (H2O2 exposure)
Result: Significantly inhibited H2O2-induced IKKβ phosphorylation and upregulated HO-1 protein expression in SH-SY5Y cells.

Cell Viability Assay[1]

Cell Line: IKKβ-overexpressing SH-SY5Y cells exposed to H2O2
Concentration: 5 μM; 1200 ng/mL IKKβ plasmid
Incubation Time: 18 h (pretreatment); 24 h (H2O2 exposure); 6 h (transfection)
Result: Significantly increased cell viability after H2O2 damage in cells with normal IKKβ expression.
Almost completely abolished this protective effect in IKKβ-overexpressing cells.
Parmacokinetics
Species Dose Route T1/2 Tmax Cmax AUC0-t AUC0-∞ MRT0-t MRT0-∞ F
Mice[1] 15 mg/kg i.p. 7.57 h 0.25 h 56.3 ng/mL 192.0 ng·h/mL 205.0 ng·h/mL 4.99 h 7.19 h 22.1 %
In Vivo

JHB-17 (15 mg/kg; i.p.; administered 2 h before modeling) significantly reduces cerebral infarct volume and improves neurological function in rat MCAO/R model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

432.34

Formula

C23H23Cl2NO3
SMILES

O=C1/C(CC/C1=C\C2=CC=C(O)C(O)=C2)=C/C3=CC=C(N(CCCl)CCCl)C=C3
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

JHB-17 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

JHB-17JHB17JHB 17IKKHeme Oxygenase (HO)Keap1-Nrf2Reactive Oxygen Species (ROS)FerroptosisIκB kinaseI kappa B kinase Heme OxygenaseSLC7A11glutathioneferroptosislipid peroxidationcerebral ischemia-reperfusion injuryIKKβNrf2HO-1intracellular ROSSH-SY5Y cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
JHB-17
Cat. No.:
HY-184115
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.